Annual Drug Patent Expirations for DOVATO
Dovato is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.
Drug patent litigation for DOVATO.
This drug has two hundred and twenty-six patent family members in forty-eight countries.
The generic ingredient in DOVATO is dolutegravir sodium; lamivudine. One supplier is listed for this compound. Additional details are available on the dolutegravir sodium; lamivudine profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
